IDEXX LABORATORIES, INC. Financials IDEXX Laboratories, Inc.
Equities
IDXX
US45168D1046
Medical Equipment, Supplies & Distribution
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 499.3 USD | +2.06% |
|
+4.82% | -10.04% |
| Apr. 01 | Elanco Animal Health Appoints Two Ancora Holdings' Nominees to Board | MT |
| Apr. 01 | Elanco appoints two directors after settling with activist Ancora | RE |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 22,400 | 42,639 | 55,833 | 33,786 | 46,098 | 41,487 | - | - |
| Enterprise Value (EV) 1 | 23,298 | 43,163 | 56,612 | 35,022 | 46,592 | 41,947 | 41,750 | 41,393 |
| P/E ratio | 53.4 x | 74.5 x | 76.6 x | 50.8 x | 55.2 x | 44.9 x | 39.5 x | 34.7 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | 9.31 x | 15.8 x | 17.4 x | 10 x | 12.6 x | 10.4 x | 9.45 x | 8.61 x |
| EV / Revenue | 9.68 x | 15.9 x | 17.6 x | 10.4 x | 12.7 x | 10.5 x | 9.51 x | 8.59 x |
| EV / EBITDA | 36.4 x | 54.6 x | 54.6 x | 34.7 x | 38.4 x | 31.5 x | 28.1 x | 25.3 x |
| EV / FCF | 76.6 x | 79.8 x | 89 x | 88.9 x | 60.3 x | 49.1 x | 43.6 x | 39.4 x |
| FCF Yield | 1.31% | 1.25% | 1.12% | 1.13% | 1.66% | 2.04% | 2.3% | 2.54% |
| Price to Book | 127 x | 67.5 x | 82.6 x | 55.6 x | 31 x | 20.4 x | 15.3 x | 13.4 x |
| Nbr of stocks (in thousands) | 85,783 | 85,300 | 84,794 | 82,817 | 83,052 | 83,089 | - | - |
| Reference price 2 | 261.1 | 499.9 | 658.5 | 408.0 | 555.0 | 499.3 | 499.3 | 499.3 |
| Announcement Date | 1/31/20 | 2/2/21 | 2/2/22 | 2/6/23 | 2/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 2,407 | 2,707 | 3,215 | 3,367 | 3,661 | 3,989 | 4,392 | 4,816 |
| EBITDA 1 | 640.9 | 790.5 | 1,037 | 1,011 | 1,212 | 1,333 | 1,488 | 1,639 |
| EBIT 1 | 552.8 | 694.5 | 932 | 898.8 | 1,097 | 1,216 | 1,364 | 1,536 |
| Operating Margin | 22.97% | 25.66% | 28.99% | 26.69% | 29.97% | 30.49% | 31.06% | 31.89% |
| Earnings before Tax (EBT) 1 | 522.2 | 662 | 902.7 | 860 | 1,061 | 1,182 | 1,322 | 1,495 |
| Net income 1 | 427.7 | 581.8 | 744.8 | 679.1 | 845 | 927.5 | 1,045 | 1,178 |
| Net margin | 17.77% | 21.49% | 23.17% | 20.17% | 23.08% | 23.25% | 23.8% | 24.47% |
| EPS 2 | 4.890 | 6.710 | 8.600 | 8.030 | 10.06 | 11.12 | 12.63 | 14.37 |
| Free Cash Flow 1 | 304.2 | 541.1 | 636 | 394.1 | 772.9 | 853.7 | 958.4 | 1,049 |
| FCF margin | 12.64% | 19.99% | 19.78% | 11.71% | 21.11% | 21.4% | 21.82% | 21.79% |
| FCF Conversion (EBITDA) | 47.47% | 68.45% | 61.35% | 39% | 63.77% | 64.04% | 64.42% | 64.02% |
| FCF Conversion (Net income) | 71.12% | 93.01% | 85.39% | 58.04% | 91.46% | 92.03% | 91.69% | 89.05% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Announcement Date | 1/31/20 | 2/2/21 | 2/2/22 | 2/6/23 | 2/5/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q3 | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 | 2025 Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 810.4 | 801.1 | 836.5 | 860.5 | 841.7 | 828.6 | 900.2 | 943.6 | 915.5 | 901.6 | 966.2 | 1,025 | 1,005 | 996.3 | 1,064 |
| EBITDA 1 | 252.4 | 226.9 | 274.9 | 207.2 | 281.5 | 255.2 | 308.7 | 324 | 304.3 | 275 | 315.6 | 349.6 | 336.2 | 320 | - |
| EBIT 1 | 226 | 199.2 | 248.3 | 179.1 | 253 | 226.5 | 280.4 | 296.1 | 275.3 | 245.3 | 291.1 | 326.8 | 311.3 | 288.7 | 335.8 |
| Operating Margin | 27.88% | 24.86% | 29.69% | 20.81% | 30.06% | 27.34% | 31.15% | 31.38% | 30.07% | 27.21% | 30.13% | 31.89% | 30.98% | 28.98% | 31.57% |
| Earnings before Tax (EBT) 1 | 219 | 191.9 | 241.5 | 171.1 | 234.2 | 213.2 | 267.7 | 285.9 | 267.9 | 239.7 | 285.4 | 317.8 | 302.2 | 278.8 | 328.2 |
| Net income 1 | 175.2 | 162.8 | 194 | 132 | 180.9 | 172.2 | 214.1 | 224.2 | 212.2 | 194.5 | 222.9 | 247.7 | 236.7 | 219.9 | 259.1 |
| Net margin | 21.62% | 20.32% | 23.19% | 15.34% | 21.5% | 20.78% | 23.78% | 23.76% | 23.18% | 21.58% | 23.07% | 24.17% | 23.56% | 22.07% | 24.36% |
| EPS 2 | 2.030 | 1.890 | 2.270 | 1.560 | 2.150 | 2.050 | 2.550 | 2.670 | 2.530 | 2.320 | 2.675 | 2.981 | 2.847 | 2.653 | 3.123 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 11/2/21 | 2/2/22 | 5/4/22 | 8/2/22 | 11/1/22 | 2/6/23 | 5/2/23 | 8/1/23 | 11/1/23 | 2/5/24 | - | - | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 897 | 525 | 779 | 1,236 | 494 | 461 | 264 | - |
| Net Cash position 1 | - | - | - | - | - | - | - | 93.2 |
| Leverage (Debt/EBITDA) | 1.4 x | 0.6636 x | 0.7517 x | 1.223 x | 0.4075 x | 0.3455 x | 0.1771 x | - |
| Free Cash Flow 1 | 304 | 541 | 636 | 394 | 773 | 854 | 958 | 1,049 |
| ROE (net income / shareholders' equity) | 509% | 144% | 113% | 105% | 80.7% | 50.7% | 41.9% | 40.1% |
| ROA (Net income/ Total Assets) | 25.4% | 28.2% | 31.5% | 26.2% | 28.1% | 27.1% | 26.9% | 26.4% |
| Assets 1 | 1,685 | 2,064 | 2,366 | 2,592 | 3,003 | 3,428 | 3,892 | 4,471 |
| Book Value Per Share 2 | 2.060 | 7.410 | 7.970 | 7.340 | 17.90 | 24.50 | 32.60 | 37.10 |
| Cash Flow per Share 2 | 5.250 | 7.470 | 8.730 | 6.420 | 10.80 | 12.70 | 14.10 | 15.90 |
| Capex 1 | 155 | 107 | 120 | 149 | 134 | 179 | 192 | 202 |
| Capex / Sales | 6.44% | 3.95% | 3.72% | 4.42% | 3.65% | 4.49% | 4.38% | 4.2% |
| Announcement Date | 1/31/20 | 2/2/21 | 2/2/22 | 2/6/23 | 2/5/24 | - | - | - |
1USD in Million2USD
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
14
Last Close Price
499.3
USD
Average target price
585.8
USD
Spread / Average Target
+17.33%
EPS Revisions
- Stock Market
- Equities
- IDXX Stock
- Financials IDEXX Laboratories, Inc.
